Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of
intravesical cis-urocanic acid in patients with primary or recurrent non-muscle invasive
bladder cancer.
Phase:
Phase 1
Details
Lead Sponsor:
BioCis Pharma Ltd
Collaborators:
FinnMedi Oy Tampere University Hospital Turku University Hospital